Mostrar el registro sencillo del ítem
dc.contributor.author
Rey, Rodolfo Alberto
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2023-08-29T17:58:37Z
dc.date.issued
2022-10
dc.identifier.citation
Rey, Rodolfo Alberto; Considerations when treating male pubertal delay pharmacologically; Taylor & Francis; Expert Opinion on Pharmacotherapy; 23; 17; 10-2022; 1903-1914
dc.identifier.issn
1465-6566
dc.identifier.uri
http://hdl.handle.net/11336/209806
dc.description.abstract
Introduction: Delayed puberty , usually affects psychosocial well-being. Patients and their parents show concern about genital development and stature. The condition is transient in most of the patients; nonetheless, the opportunity should not be missed to diagnose an underlying illness. Areas covered: The etiologies of pubertal delay in males and their specific pharmacological therapies are discussed in this review. Expert opinion: High-quality evidence addressing the best pharmacological therapy approach for each etiology of delayed puberty in males is scarce, and most of the current practice is based on small case series or unpublished experience. Male teenagers seeking attention for pubertal delay most probably benefit from medical treatment to avoid psychosocial distress. While watchful waiting is appropriate in 12- to 14-year-old boys when constitutional delay of growth and puberty (CGDP) is suspected, hormone replacement should not be delayed beyond the age of 14 years. When hypogonadism is diagnosed, hormone replacement should be proposed by the age of 12 years. Testosterone replacement has been used for decades and is fairly standardized. Aromatase inhibitors have arisen as an interesting alternative. Gonadotrophin therapy seems more physiological in patients with central hypogonadism, but its efficacy and timing still need to be established.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Taylor & Francis
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
AROMATASE INHIBITOR
dc.subject
CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY (CDGP)
dc.subject
GONADOTROPHIN-RELEASING HORMONE (GNRH)
dc.subject
HUMAN CHORIONIC GONADOTROPHIN (HCG)
dc.subject
HYPERGONADOTROPHIC HYPOGONADISM
dc.subject
HYPOGONADOTROPHIC HYPOGONADISM
dc.subject
LETROZOLE
dc.subject
RECOMBINANT FOLLICLE-STIMULATING HORMONE (R-FSH)
dc.subject
TESTOSTERONE ENANTHATE
dc.subject
TESTOSTERONE UNDECANOATE
dc.subject.classification
Endocrinología y Metabolismo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Considerations when treating male pubertal delay pharmacologically
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-07-07T23:02:00Z
dc.journal.volume
23
dc.journal.number
17
dc.journal.pagination
1903-1914
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Rey, Rodolfo Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas "Dr. César Bergada". Gobierno de la Ciudad de Buenos Aires. Centro de Investigaciones Endocrinológicas "Dr. César Bergada". Fundación de Endocrinología Infantil. Centro de Investigaciones Endocrinológicas "Dr. César Bergada"; Argentina
dc.journal.title
Expert Opinion on Pharmacotherapy
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/14656566.2022.2138743
Archivos asociados